Redhill Biopharma Ltd. (NASDAQ:RDHL) Shares Shorted: Short Interest Down 52.3% in October

Redhill Biopharma Ltd. (NASDAQ:RDHL – Get Free Report) saw a large decrease in short interest in October. As of October 30th, there was short interest totaling 61,151 shares, a decrease of 52.3% from the October 15th total of 128,328 shares. Based on an average daily trading volume, of 132,590 shares, the short-interest ratio is presently 0.5 days. Currently, 0.7% of the company’s stock are sold short.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded Redhill Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, October 6th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat, the stock currently has a consensus rating of “Sell”.

View Our Latest Analysis on RDHL

Redhill Biopharma Price Performance

Shares of RDHL traded down $0.01 during trading hours on Monday, reaching $0.37. 26,730 shares of the company traded hands, compared to its average volume of 802,904. Redhill Biopharma has a 12-month low of $0.36 and a 12-month high of $1.60. The business has a fifty day moving average price of $0.50 and a 200-day moving average price of $0.77.

Redhill Biopharma Company Profile

(Get Free Report)

RedHill Biopharma is a biopharmaceutical company founded in 2009 and based in Israel, with a focus on developing and commercializing treatments for gastrointestinal and infectious diseases. Its activities have included drug development, regulatory and clinical research, and product commercialization, particularly in the United States. The company’s product portfolio has included Talicia, a combination therapy approved in the United States for adults with Helicobacter pylori infection, and Aemcolo, an antibiotic approved for certain cases of travelers’ diarrhea.

Recommended Stories

Receive News & Ratings for Redhill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.